Most Extensive Face Transplant Ever Undertaken on Burn Victim

Jacob Newberger is a Pennsylvania professional with past experience designing automated systems at Panacea Technologies. With a longstanding interest in medicine, Jacob Newberger is particularly focused on developments in the orthopedics and transplant surgery spheres.

In many ways 2015 was a breakthrough year in medicine, with milestones including the most extensive face transplant ever undertaken. The pioneering treatment involved a volunteer firefighter who suffered severe burns when attempting to rescue a person he believed to be trapped in a burning home. The third-degree burns took all of his head and eyebrow hair, as well as his ears, and made him virtually unrecognizable to friends and family.

An innovative U.S. surgeon undertook a transplant that used donated tissue encompassing the forehead, face, scalp, ears, and eyelids. The surgeon also replaced a certain number of the nerves, blood vessels, and muscles under the skin. The result was a “hybrid” face that combined some of the patients’ facial features with those of his donor, who had been killed in a cycling incident.

Three months after the surgery, the patient was described as being in excellent condition and leading an independent life. In particular, transplant areas such as the ears and lips exhibited good color, a sign that blood circulation has been repaired.

Professional Athletes Benefit from Improvements in ACL Repair

An automation validation engineer with Panacea Technologies, Inc., in Montgomeryville, Pennsylvania, Jacob Newberger maintains a number of interests outside of his profession. Among other things, Jacob Newberger follows the latest advances in orthopedic surgery.

Orthopedic injuries come in all shapes and sizes, ranging from carpal tunnel syndrome to more serious conditions such as a tear in the anterior cruciate ligament (ACL) in the knee. Professional athletes are particularly susceptible to ACL tears, especially basketball and football players, such as Chicago Bulls guard Derrick Rose and Adrian Peterson of the Minnesota Vikings. In the past, these kinds of injuries could spell the end of a player’s career or, at the very least, prevent players from ever regaining their previous form.

However, advances in modern medicine have allowed several players to successfully rebound from an ACL tear. Peterson’s story is most often cited as an example of how far sports and orthopedic medicine have come. In 2012, Peterson returned to the National Football League (NFL) only six months after tearing his ACL. The short recovery period was itself an impressive feat. However, Peterson did more than just rebound from his ACL tear. The season following his surgery, the running back averaged 19 yards per carry, a career best, and came within one carry of breaking the league’s single-season rushing record. While an ACL tear is still a very serious injury for pro athletes, such recovery stories provide hope for them as well as average people who simply wish to regain full range of motion in their knee.

An Overview of Stem Cell Therapy for Orthopaedics

Jacob Newberger currently works at Panacea Technologies, Inc., as an automation validation engineer. Outside of work Jacob Newberger enjoys learning about medicine, particularly transplant surgeries and orthopaedic procedures.

In recent years stem cell therapy has been used to treat a number of conditions throughout the human body, including several musculoskeletal disorders. Bone grafts and surgical implants represented the primary medical response to orthopaedic disorders for many years, though more recently stem cell tissue engineering has attracted considerable interest among the orthopaedic community.

Medical professionals have long been aware of bone morphogenetic proteins thanks to the discovery of Marshall Urist, MD. While a number of proteins have been identified as osteoinductive and osteoconductive throughout the process of osteogenesis, the smallest variables in the body’s microenvironment can dictate the success of a protein implant procedure. Stem cells, on the other hand, can be viewed as blank pages. Unlike proteins, each stem cell is capable of producing a variety of paracrine modulators. A stem cell’s capacity for renewed ontogeny allows the cell to develop in any number of ways, an infinitely easier process than mixing and matching proteins until the correct combination is discovered.

Advancements in Robotic Automation for the Medical Industry

The founder of Need a Tutor? tutoring service, Jacob Newberger has tutored over 40 high school and university students for a total of more than 500 hours. A graduate of Pennsylvania State University with a bachelor of science in mechanical engineering, he received the best engineered design award for his autonomous system navigation and driver augmentation vehicle. In addition to mechanical engineering, Jacob Newberger is interested in medicine and automation.

From an initial period of hesitation and resistance to robotic automation, the medical industry has made steps to embrace the technology. Especially useful in laboratories and packaging, robots can perform repetitive tasks quickly and precisely. As technology has improved, demand for it has grown, and the industry now is expected to grow at a compound annual growth rate of nearly 10 percent.

Recently, a robot called Eve and developed by the University of Manchester, Aberystwyth University, and the University of Cambridge, independently discovered a compound useful in the fight against malaria. Capable of screening over 10,000 compounds every day, Eve is able to create and test a hypothesis with a special focus on neglected tropical diseases. Over time, robotic automation may be used for a wider range of applications throughout the industry.

Panacea Technologies and Process Analytical Technology

As an undergraduate at Pennsylvania State University, Jake Newberger earned a bachelor of science in mechanical engineering. While there, Jake Newberger was part of the robotics club and served as president of the school’s chapter of Alpha Epsilon Pi. Presently, Jacob Newberger serves as an automation validation engineer with Panacea Technologies, Inc.

Primarily used by chemical and pharmaceutical companies, Process Analytical Technology (PAT) allows users to obtain time-critical data for designing, analyzing, and controlling manufacturing processes. It enables companies to recognize critical points at all stages of the product lifecycle, from the acquisition of raw materials to the creation of the final product. These systems use methods ranging from chemometric analyzers to multivariate data tools to provide readings to clients. Moreover, PAT systems can interface with most automation systems.

Panacea Technologies has been on the forefront of PAT systems, particularly those developed by the pharmaceutical leader Siemens, known as SIPAT. For the past five years, it has installed SIPAT systems for a major pharmaceutical company, and this network ranks among the biggest PAT systems in the world. Moreover, Panacea Technologies further aids its client by providing ongoing end-to-end services, IQ and OQ validation maintenance, system expansion, and other forms of support. Upon the release of SIPAT 4.0, the company upgraded the entity’s worldwide system so that it can remain an information technology leader.

New Liver Transplant Studies Show an Advantage for Living Donor Organs

Currently an automation validation engineer with Panacea Technologies, Jake Newberger also has experience as a home automation installer and programmer. Jacob Newberger graduated from Pennsylvania State University, where he earned a bachelor of science in mechanical engineering and was recognized for his autonomous system navigation and driver augmentation project. Still interested in mechanical issues, Jake Newberger enjoys learning about advances in automation, robotics, and transplant surgery.

Since a kidney from one living twin was transplanted into an identical twin brother in 1954, living donor transplantation has become more common for organs like the kidney, liver, intestine, and even the heart under special circumstances. Because the liver can regenerate to an extent after the transplant, it is one of the most commonly performed operations. In fact, a recent study from the University of Pennsylvania showed that patients who receive organs, specifically the liver, from living donors are more likely to live longer than those who receive organs from deceased donors: 83 percent of living donation patients survive at least three years, compared to 78 percent of recipients of organs from deceased donors. Other contributing factors included the experience of the hospital performing the liver transplant as well as the reason for the transplant. Patients with autoimmune hepatitis and cholestatic liver disease benefited the most.

FDA Announces Drug Approvals in 2014 First Quarter

Working as an automation validation engineer for Pennsylvania-based Panacea Technologies, Inc., Jacob “Jake” Newberger creates equipment with PLC, Batch, SCADA, and DCS systems. In the summer of 2006, Jake Newberger worked as an intern for Prototype Productions, Inc., located in Ashburn, Virginia, where he helped with the design and assembly of biomedical devices. He remains interested in the research and development as well as manufacturing of pharmaceuticals.

Each quarter, the U.S. Food and Drug Administration (FDA) announces its list of pharmaceutical drug approvals. In the first quarter of 2014, the FDA approved six new molecular entities (NMEs). Compared with the same quarter in the previous year, this is a decline in approvals, since nine were approved in 2013. This marks the lowest number of approvals in a single quarter since 2000. In 2013 alone, the FDA approved 27 drugs, compared with 39 in 2012. Experts claim this decrease is due to decline in drugs submitted for review.

With the recent influx of public healthcare programs, customers are demanding lower costs for their pharmaceuticals. To remain competitive, analysts stress that the U.S.-based manufacturers must find ways to reduce their overall costs, otherwise insurance companies may seek pharmaceuticals from other countries.